Neurovex
neurovexine
Phase IIStatus: Pending
Therapeutic Area: Neurology•Manufacturer: BrainScience Corp
Overview
Description
A first-in-class tau aggregation inhibitor for the treatment of Alzheimer's disease.
Mechanism of Action
Prevents the aggregation of tau protein, reducing neurofibrillary tangle formation and slowing disease progression.
Indication
Early-stage Alzheimer's disease.
Market Projections
Financial outlook and market data
$3200M
Estimated Revenue
$25.0B
Market Size
12.5%
Growth Rate
2030
Peak Sales Year
Projected Revenue Growth
20242030
Clinical Development Timeline
Progress through clinical trial phases
✓
Preclinical
Completed
✓
Phase I
Completed
3
Phase II
In Progress
4
Phase III
Not Started
5
Approved
Not Started
| Phase | Status | Timeline | Participants | Primary Endpoint | Results |
|---|---|---|---|---|---|
| Preclinical | Completed | 2019-06 - 2020-12 | - | - | Reduced tau pathology in transgenic mice |
| Phase I | Completed | 2021-03 - 2022-06 | 80 | Safety and CSF penetration | Good CNS penetration, acceptable safety |
| Phase II | In Progress | 2022-11 | 350 | Change in CDR-SB | - |
| Phase III | Not Started | - | - | - | - |
| Approved | Not Started | - | - | - | - |
Regulatory Approval Status
Approval status across different regions
No regulatory submissions yet.
This drug is still in clinical development.